Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
17:31
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

WFH 2014 World Congress

 

11-15 May 2014 Melbourne
FAQs
   
Discussion forum - WFH 2014 World Congress
    Topic - Inhibitors, Pathogenesis, Prevention and Treatment

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Effect of vaccinations on inhibitor development in patients with severe hemophilia A  S.M. Hashemi 1      5/7/2014 1:21:00 PM  
Experience of Prophylaxis with Activated Prothrombin Complex Concentrate in A Child with Hemophilia B and Inhibitor  Alphan Kupesiz 1      5/6/2014 5:51:00 PM  
Observational Immune Tolerance Induction research program (ObsITI) - a multifaceted approach to explore immune tolerance induction  Carmen Escuriola 1      5/5/2014 5:27:00 PM  
Low incidence of FVIII inhibitors in patients treated with plasma derived FVIII concentrates and the outcomes of immune tolerance induction with FVIII/vWF concentrates  Tatiana Prigancova 1      4/24/2014 6:24:00 PM  
Severe Haemophilia A with high-titre inhibitors and a complicated clinical course  Rajendra Thejpal 1      4/23/2014 11:56:00 PM  
Recurrence of Inhibitors after Immune Tolerance Induction: A Retrospective Single-Center Study  Maricel Miguelino 1      4/23/2014 10:12:00 PM  
Inhibitor Eradication in Haemophilia: a European Survey  Katharina Holstein 1      4/23/2014 10:00:00 PM  
Uptake and timing of inhibitor screening in non-severe haemophilia A: results of a pan-London evaluation  Paul Batty 1      4/23/2014 9:45:00 PM  
F8 genotype specific inhibitor risks in Argentine patients with severe HA and particular risk estimation of different mutation types.  Carlos De Brasi 1      4/23/2014 8:37:00 PM  
Prospective ADVATE Immune Tolerance Induction Registry (PAIR) Interim Results: Success Rates Continue to Support Published Literature  Amy Shapiro 1      4/23/2014 8:02:00 PM  
Transcatheter arterial chemoemboliazation of hepatocellular carcinoma: management of one hemophilia A patient with inhibitor  Takeshi Matsumoto 1      4/23/2014 5:34:00 PM  
Bleeding Phenotype And Clinical Management Of Children With Severe Hemophilia A And Inhibitors: A Follow-up Cohort Study.  Maria Elisa Mancuso 1      4/23/2014 3:38:00 PM  
Slovenian National data for inhibitor appearance in haemophilia A (HA) patients  majda benedik dolnicar 1      4/23/2014 2:44:00 PM  
Inhibitors increase the burden of disease in nonsevere haemophilia A patients - treatment strategies to obtain haemostasis.  Alice van Velzen 1      4/23/2014 1:24:00 PM  
Postoperative TGA(Thrombin Generation Assay)monitoring of homeostasis of haemophilia patients with inhibitor  fujihiko minamoto 1      4/23/2014 12:17:00 PM  
Early Elimination of Factor VIII Inhibitor by ITI with High Dose Immunoglobulin in Hemophilia A Children  Yoko Mizoguchi 1      4/23/2014 11:41:00 AM  
Immune monitoring of FVIII inhibitor development in the Hemophilia Inhibitor PUP Study (HIPS)  Christoph Hofbauer 1      4/23/2014 11:22:00 AM  
Elective Orthopaedic Surgery In Patients With Haemophilia And Inhibitors: Still A Big Challenge For Haematologists?  Maria Elisa Mancuso 1      4/23/2014 9:56:00 AM  
The Development of Anti-Factor VIII Antibodies Associated with the Change of Serum BAFF Level in Hemophilia A mice  Shin-Nan Cheng 1      4/23/2014 8:25:00 AM  
Surgery and Invasive procedure with bypassing agents in hemophilic patients with inhibitors : a single center experience  Young Shil Park 1      4/23/2014 8:12:00 AM  
Two consecutive life threatening bleeding episodes in hemophilia A patients with high responding inhibitors  Jung Woo Han 1      4/23/2014 8:05:00 AM  
Continues ITI versus prophylaxis with NovoSeven; An immune tolerance induction failure cost analysis model.  Chris Barnes 1      4/23/2014 6:05:00 AM  
Pseudotumor causing duodenal fistula and secondary tumor rupture in a hemophilia B patient with high responding inhibitors : case report  Jung Woo Han 1      4/23/2014 5:11:00 AM  
Postauthorization safety surveillance study (PASS) of hemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings  Pablo Rendo 1      4/22/2014 8:12:00 PM  
Selection and characterization of single-chain variable antibody fragments (scFvs) specific for anti-FVIII antibodies  Kerstin Brettschneider 1      4/22/2014 7:43:00 PM  
Experience of prophylactic and on demand treatment of inhibitory form of haemophilia B in children using recombinant activated FVII.  Vladimir Vdovin 1      4/22/2014 4:40:00 PM  
Surgical procedures as a risk factor for the inhibitor development in young children with Haemophilia  Rosemarie Shaw-Schwyzer 1      4/22/2014 3:49:00 PM  
Comparison of historic on-demand versus prospective on-demand and prophylaxis bleeding episodes in hemophilia A and B patients with inhibitors treated with FEIBA NF  Srilatha Tangada 1      4/22/2014 2:33:00 PM  
Does a once weekly prophylaxis with low dose factor VIII in PUPs with haemophilia A decrease the risk of inhibitor development? Results of a survey in centers of the Competence Network Hemorrhagic Diatheses East.  Ralf Knoefler 1      4/22/2014 12:03:00 PM  
Successful Management of Orthopedic Surgery in a Patient with Congenital Haemophilia A with Inhibitors from Guatemala, Central America. A Case Report  Marta Julia Lopez 1      4/22/2014 2:54:00 AM  
Surveillance for Hemophilia Inhibitors in the United States  Mike Soucie 1      4/21/2014 8:23:00 PM  
Natural course of inhibitors in Korean Hemophilia A patients  Eun Jin Choi 1      4/21/2014 7:42:00 AM  
Combined (sequential and parallel) therapy with by-passing agents and antifibrinolytics in patients with hemophilia and inhibitor.  Nebojsa Rajic 1      4/20/2014 9:16:00 PM  
A Phase III clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in hemophilia patients with inhibitors: hemostatic efficacy and safety  YUICHI SHINKODA 1      4/17/2014 9:16:00 AM  
The association of factor VIII genotypes and HLA DRB115, tumor necrosis factor -308A and interleukin -10-1082G alleles on inhibitor development in Thai patients with hemophilia A  Ampaiwan Chuansumrit 1      4/2/2014 2:55:00 AM  
FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa.  Tayou Tagny Claude 1      3/23/2014 7:50:00 AM  
A Status of Immune Suppression in Hemophilia A with Developed Factor VIII Inhibitors.  Zhenping Chen 1      3/14/2014 8:47:00 AM  
       




Most viewed poster for this congress
Poster: 1
Visits: 2526
Title: A WEB SITE TO IMPROVE MANAGEMENT OF PATIENTS WITH INHERITED BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT: RESULTS AT 2 YEARS
Authors: Annarita Tagliaferri ,
Centre: Centro di Riferimento Regionale per la cura dellEmofilia

Poster most viewed in this topic
Poster: 63
Visits: 314
Title: A Phase III clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in hemophilia patients with inhibitors: hemostatic efficacy and safety
Authors: YUICHI SHINKODA ,
Centre: Kagoshima City Hospital


 








PosterSessionOnline
Logo Draft
 
Logo Cert